Physician profile
Abdullah Ladha
NPI 1033341672
$17,251.10
in general payments reported to CMS, 2019-2025
25 companies · $14K in 2025
The $14K reported for 2025 was more than what 81% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $136 · 2021: $1,626 · 2022: $313 · 2023: $328 · 2024: $566 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,478 · Travel and Lodging: $247 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,256.25 |
| Food and Beverage | $1,478.38 |
| Travel and Lodging | $246.82 |
| Education | $194.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $11,446.43 | 2025 | Revuforj |
| Pfizer INC. | $3,994.59 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $313.71 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.83 | 2021-2025 | Livtencity, Iclusig |
| Novartis Pharmaceuticals Corporation | $157.62 | 2023-2025 | |
| Alphatec Spine, INC | $135.04 | 2022 | |
| Janssen Biotech, INC. | $125.12 | 2024-2025 | Darzalex, Talvey |
| Incyte Corporation | $118.10 | 2023 | Jakafi |
| Blueprint Medicines Corporation | $105.20 | 2022-2024 | Ayvakit |
| Abbvie INC. | $88.06 | 2023-2025 | |
| Daiichi Sankyo INC. | $79.94 | 2023-2025 | Vanflyta |
| Alexion Pharmaceuticals, INC. | $57.61 | 2024-2025 | Ultomiris |
| Adc Therapeutics America, INC. | $46.71 | 2023-2024 | |
| Celgene Corporation | $44.20 | 2021-2025 | Breyanzi |
| Sobi, INC | $42.12 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.09 | 2025 | |
| Genmab U.S., INC. | $32.72 | 2025 | Epkinly |
| Astellas Pharma US INC | $31.17 | 2023 | Xospata |
| Kite Pharma, INC. | $30.37 | 2025 | Yescarta |
| Legend Biotech USA INC. | $27.59 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $24.62 | 2024 | Onivyde, Somatuline Depot |
| Amgen INC. | $23.98 | 2022 | |
| Sumitomo Pharma America, INC. | $23.73 | 2024 | Orgovyx |
| Astrazeneca Pharmaceuticals LP | $23.07 | 2024 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Ladha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.